Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adefovir dipivoxil

Drug Profile

Adefovir dipivoxil

Alternative Names: Adesera; Bis-POM PMEA; GS 0840; GS 840; Hepsera; Piv2PMEA

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Columbia University; Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague)
  • Class Analgesics; Anti-inflammatories; Antiretrovirals; Phosphonic acids; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued HIV infections; Rheumatic disorders

Most Recent Events

  • 27 Feb 2017 Gilead Sciences has patent protection for Adefovir dipivoxil in Europe and USA (Gilead Sciences 10-K, February 2017)
  • 01 Sep 2012 Gilead Sciences completes a phase I/II trial in Hepatitis B (Prevention, Combination therapy) in USA (PO) (NCT01146808)
  • 09 Dec 2005 Launched for Hepatitis B in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top